Navigation Links
Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab

Berlin, Germany, June 7 2012: Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20*.

The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) was carried out in 646 biologic-nave patients with active RA and inadequate response to methotrexate. At four weeks, 42.5% of patients in the abatacept group achieved ACR20 response versus 47.6% in the adalimumab group. This remained comparable until the end of year one. At 12 months, ACR50* response was similar between the two groups (46.2% in the abatacept group and 46% in the adalimumab group). ACR70* response was 29.2% versus 26.2% in the abatacept group and adalimumab groups respectively. These data show the similar time course of response. Inhibition of radiographic progression was also similar in both arms.

"There have been very few head-to-head trials in rheumatoid arthritis and, to date, there have been no randomised, controlled studies directly comparing the safety and efficacy of different biologic disease-modifying anti-rheumatic drugs (DMARDs) using the combination of a biologic medication and methotrexate which is the most commonly prescribed treatment approach in moderate to severe RA," said Dr. Michael Schiff, University of Colorado, USA and lead author of the study. "This study is a great leap forward for us and our patients as it shows there is another treatment option that is as effective and as safe as adalimumab."

The AMPLE study is a randomised, investigator-blinded study of 24 months, with a 12 month efficacy primary endpoint. Patients were stratified by disease activity and randomised to either 125mg subcutaneous abatacept (without an IV load) weekly or 40mg subcutaneous adalimumab bi-weekly, in combination with a stable dose of methotrexate. The primary endpoint of the trial was non-inferiority by ACR20 response at 12 months with a non-inferiority margin of 12%.

There was a similar rate of adverse events, serious adverse events, serious infections and malignancies in both groups.

More patients in the abatacept arm experienced autoimmune adverse events (3.1% versus 1.2%), but none were considered to be serious. There were also fewer discontinuations due to adverse events (2.5% versus 6.1%) and serious infections (0 versus 5 discontinuations) in the abatacept arm. Injection site reactions also occurred in fewer abatacept patients (3.8% versus 9.1%, 95% confidence interval: -5.37 (-9.13, -1.62) p=0.006).

Abatacept (Orencia), which is produced by Bristol-Myers Squibb, is a first-in-class biologic which works to reduce co-stimulation of T-cells, which in turn reduces activation of other cells in the RA inflammatory process, thereby blocking the pain, inflammation and joint progression pathways in RA.

Adalimumab (Humira) is produced by Abbott and is a biologic TNF-blocker, or anti-TNF. Adalimumab works by binding to TNF-alpha receptors, thereby blocking the pain, inflammation and joint progression pathways in RA.


Contact: Candice Debleu
European League Against Rheumatism

Related medicine news :

1. For Lung Disorder, Spiriva Beat Serevent in Head-to-Head Trial
2. Newer Drugs Beat Gleevec in Head-to-Head Trials
3. UT Southwestern investigators perform head-to-head comparison of incontinence treatments
4. Exercise Appears to Ease Nerve-Damage Pain in Rat Study
5. New Medicine Might Fight Drug-Resistant TB, Study Says
6. Exercise Controls Weight in White Girls Better Than in Black Girls: Study
7. Gout Flare-ups Rise Sharply With Certain Foods: Study
8. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
9. Humans Can Sniff Out Old Age in Others, Study Shows
10. Infant Smarts Similar With Different Types of Formula: Study
11. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology: